4 results about "Complete remission" patented technology

The present application provides a set of complete innovative technical solutions from target discovery to treatment intervention for the immune escape and drug resistance recurrence problems existing in the clinical treatment of multiple myeloma (MM). It is found that Siglec7 is mainly highly expressed on the surface of NK cells, and the proportion and expression intensity of Siglec7 positive NK cells are significantly higher than those of complete remission and non-tumor controls; further, Siglec7 monoclonal antibody is prepared, and when the anti-Siglec7+CD38 monoclonal antibody (such as daratumumab) is used, a significant synergistic anti-tumor effect can be produced in vitro and in vivo. The technical solution completely constructs the research and development chain of "marker discovery-target verification-drug development-treatment application", and provides a new target, specific antibody drug and innovative combined drug regimen for the precise diagnosis, prognosis and especially immunotherapy of refractory and relapsed patients with multiple myeloma, which has great clinical transformation value and market prospect.

This invention discloses a neoadjuvant therapy efficacy prediction system and method based on a multimodal large model and breast ultrasound, belonging to the field of medical artificial intelligence technology. The method includes: acquiring pre-treatment ultrasound images of patients and multidimensional heterogeneous text data including past medical history, ultrasound reports, and pathological indicators; unifying the format using serialization technology and inputting it into a pre-trained multimodal large model; utilizing the model's powerful cross-modal sequence modeling capabilities to mine deep implicit associations between images and medical history, and outputting a predicted probability value for pathological complete remission (pCR). The system simultaneously outputs image heatmaps and textual decision attribution prompts. This invention achieves high-precision end-to-end personalized efficacy prediction and possesses strong clinical interpretability.

This invention belongs to the field of biomedical technology and discloses exosomes derived from induced pluripotent stem cells (iPSCs) with anti-tumor activity and their application in enhancing CAR-T cell therapy. This invention is the first to discover that iPSC-derived exosomes possess inherent anti-tumor activity by directly inhibiting tumor cell proliferation, inducing apoptosis, and inhibiting migration, with a yield hundreds of times higher than that of traditional cell-derived exosomes. Through genetic engineering, the surface of the exosomes is made to display a bispecific single-chain variable fragment against PD-1 / MSLN and loaded with indole-3-propionic acid, constructing a multifunctional therapeutic platform. This platform, administered via nebulized inhalation, achieved a 66.7% complete remission rate, a 100% 80-day survival rate, and an 83.3% resistance to tumor re-challenge in an orthotopic lung cancer model when combined with CAR-T therapy, significantly outperforming existing treatment strategies. This invention provides an innovative enhancement strategy for CAR-T cell therapy in solid tumors and has significant clinical translational value.